343 research outputs found
The Soviet and Russian historians about the reasons of losses of archival documents in days of the Great Patriotic War (1941-1945)
This article emphasizes the main reasons for disappear of documents in days of th
About Development and Verification of Software for Finite Element Analysis of Beam Systems
AbstractThe distinctive paper is devoted to author's software (Windows application) for finite element analysis (FEA) of beam systems. Program application package provides convenient graphical interface to the user for quick creation of layout design in accordance with given coordinates of nodes. User can specify various boundary conditions in the corresponding nodes or apply external loads. The results of FEA are displayed in text and graphical forms (including visualization of deformed scheme). Moreover, these results can be exported into a Microsoft Word document. Open source and freeware program has been created by Microsoft Visual C++. Information about verification samples is presentedClic
PCSK9 Inhibitors in Clinical Practice: Experience of a Specialized Lipid Center
Aim. To characterize patients receiving PCSK9 inhibitors, and assess the efficiency of their treatment in a specialized lipid center.Material and methods. A retrospective analysis of the medical records of patients who visited the Lipid clinic of the National Medical Research Center for Therapy and Preventive Medicine (Moscow, Russia), receiving PCSK9 inhibitor and having lipid profile in dynamics, was carried out (n=77). Cardiovascular risk (CVR) and low-density lipoprotein cholesterol (LDL-C) target levels were evaluated in accordance with the Russian guidelines for the diagnostics and correction of dyslipidemias 2020.Results. Of 77 patients taking PCSK9 inhibitors (44.2% males, the median of age 56 [47; 66] years), the majority (64.0%) had a probable or definite familial hypercholesterolemia (FH). The proportion of other lipid metabolism disorders, pure hypercholesterolemia and combined hyperlipidemia was 21% and 15%. More than half of the patients (68.8%) had a very high CVR, mainly due to the presence of coronary heart disease (84.9%). The proportion of patients receiving PCSK9 inhibitors as monotherapy was 7.8%, in combination with high-intensity statin therapy β 33.8%, as part of triple lipid-lowering therapy (high-intensity statin, ezetimibe, PCSK9 inhibitors) β 50.6%. Addition of PCSK9 inhibitors to combined lipid-lowering therapy enabled to reduce the LDL-C level to 1.02 [0.62; 1.39] mmol/l with its total decrease from the baseline by 87.3%. While taking PCSK9 inhibitors, LDL-C <1.8 mmol/l and <1.4 mmol/l achieved at 78.3% and 57.7% FH patients with high and very high CVR, respectively. Among patients with other hyperlipidemias, 74.1% of patients with very high CVR was achieved the target LDL-C level <1.4 mmol/l.Conclusion: In a specialized lipid center, PCSK9 inhibitors are prescribed to patients with high or very high CVR, most of whom are FH patients. The effectiveness of the use of PCSK9 inhibitors in real-world practice is comparable to the results of clinical trials
Discovery of small molecules that activate RNA-methylation through cooperative binding to the METTL3/14/WTAP complex active site
Chemical modifications of RNA provide an additional, epitranscriptomic, level of control over cellular functions. N-6-methylated adenosines (m6As) are found in several types of RNA, and their amounts are regulated by methyltransferases and demethylases. One of the most important enzymes catalyzing generation of m6A on mRNA is the trimer N-6-methyltransferase METTL3-14-WTAP complex. Its activity has been linked to such critical biological processes as cell differentiation, proliferation, and death.
We used in silico-based discovery to identify small-molecule ligands that bind to METTL3-14-WTAP and determined experimentally their binding affinity and kinetics, as well as their effect on enzymatic function. We show that these ligands serve as activators of the METTL3-14-WTAP complex
A combination of three muramyl peptides derived from gramnegative bacteria in immunotherapy of chronic pyodermia
The aim of the present study was to evaluate the clinical efficacy of a standardized combination of three muramyl peptides containing a residue of meso-diaminopimelic acid (Polymuramyl), as well as effects of this immunomodulator on the lymphocyte subpopulation profile, function of circulating neutrophils, and concentrations of serum immunoglobulins in the patients with chronic recurrent pyoderma. Thirty-five men (34.5Β±10 years) with exacerbation of chronic pyoderma (osteofolliculitis, folliculitis, sycosis, furunculosis) were randomized into two groups matched by age and clinical manifestations of the disease. In the comparison group (n = 17), the patients received standard treatment. In the main group (n = 18), in addition to the same standard treatment, the patients received intramuscular injections of Polymuramyl at a dose of 200 mg daily from day 1 to 5 of the study. The overall assessment of the treatment efficacy was performed on the day 14, and at 1 and 6 months of observations. Induction and maintenance of complete clinical remission were assessed as βsignificant improvementβ; induction and maintenance of partial remission were considered to be βimprovementβ; persistent signs of skin inflammation and lack of remission were assessed as βlack of effectβ. Immunological parameters were studied on days 0 and 14, and then at 1 and 6 months of the study. Addition of Polymuramyl to the standard treatment caused a marked tendency towards increased proportion of the patients with Β«significant improvementΒ» or Β«improvementΒ» on the day 14: total ratio of the patients with any clinical improvement was 24% higher, and the relative number of the patients with "lack of effect" was five-fold lower than in the comparison group (p=0.076). A trend towards improved clinical efficacy, according to the above criteria, was maintained after 1 and 6 months of the study. At 6 months of the follow-up, the proportion of patients without pustules/furuncles in the main group (9 out of 18) exceeded that in the comparison group (3/17, p = 0.047). Significant inter-group differences and dynamics of indicators of neutrophil functions, subpopulation composition of lymphocytes and concentrations of immunoglobulins in serum were not detected. However, in the main group after the 6-month observation, there was an upward trend in the absolute number of T-cells due to CD3+CD4+ subpopulation, as well as serum IgA concentration. The results of this study are in accordance with previously published data, thus indicating the ability of Polymuramyl to accelerate regression of clinical manifestations of chronic pyoderma and induce sustained remission of this disease. At the same time, the design of present investigation and the timing of taking biological samples for laboratory tests did not allow to register significant changes in most of the studied systemic immunological parameters under the influence of immunomodulator, except for the previously described modulation at the level of pro- and anti-inflammatory cytokines
Comparative assessment of organizational aspects of medical care in Russia and France in the first quarter of the xviii century
The article identifies the features of the organization of medical care for citizens of Russia and France in the first quarter of the XVIII centuryΠ ΡΡΠ°ΡΡΠ΅ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Ρ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΠΈ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠΉ ΠΏΠΎΠΌΠΎΡΠΈ Π² Π ΠΎΡΡΠΈΠΈ ΠΈ Π€ΡΠ°Π½ΡΠΈΠΈ Π² ΠΏΠ΅ΡΠ²ΠΎΠΉ ΡΠ΅ΡΠ²Π΅ΡΡΠΈ XVIII Π²Π΅ΠΊΠ°
Bedaquiline, linezolid, pretomanid: their adverse events
The article discusses the clinical cases and tactics of treatment with bedaquiline, linezolid, and pretomanid in patients with multiple and extensive drug resistance. The main undesirable effects of bedaquiline, linezolid, pretomanid are considered and their qualitative assessment is given.Π ΡΡΠ°ΡΡΠ΅ ΡΠ°ΡΡΠΌΠΎΡΡΠ΅Π½Ρ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ»ΡΡΠ°ΠΈ ΠΈ ΡΠ°ΠΊΡΠΈΠΊΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ Π±Π΅Π΄Π°ΠΊΠ²ΠΈΠ»ΠΈΠ½ΠΎΠΌ, Π»ΠΈΠ½Π΅Π·ΠΎΠ»ΠΈΠ΄ΠΎΠΌ, ΠΏΡΠ΅ΡΠΎΠΌΠ°Π½ΠΈΠ΄ΠΎΠΌ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΌΠ½ΠΎΠΆΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΠΈ ΡΠΈΡΠΎΠΊΠΎΠΉ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΡΡΡΠΎΠΉΡΠΈΠ²ΠΎΡΡΡΡ. Π Π°ΡΡΠΌΠΎΡΡΠ΅Π½Ρ ΠΎΡΠ½ΠΎΠ²Π½ΡΠ΅ Π½Π΅ΠΆΠ΅Π»Π°ΡΠ΅Π»ΡΠ½ΡΠ΅ ΡΠ²Π»Π΅Π½ΠΈΡ Π±Π΅Π΄Π°ΠΊΠ²ΠΈΠ»ΠΈΠ½Π°, Π»ΠΈΠ½Π΅Π·ΠΎΠ»ΠΈΠ΄Π°, ΠΏΡΠ΅ΡΠΎΠΌΠ°Π½ΠΈΠ΄Π° ΠΈ Π΄Π°Π½Π° ΠΈΡ
ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½Π°Ρ ΠΎΡΠ΅Π½ΠΊΠ°
A Rapid Synthesis of Oriented Palladium Nanoparticles by UV Irradiation
Palladium nanoparticles of average size around 8 nm have been synthesized rapidly by UV irradiation of mixture of palladium chloride and potassium oxalate solutions. A rod-shaped palladium oxalate complex has been observed as an intermediate. In the absence of potassium oxalate, no Pd nanoparticles have been observed. The synthesized Pd nanoparticles have been characterized by powder X-ray diffraction (XRD), transmission electron microscopy (TEM), selective area electron diffraction and energy dispersive analysis by X-rays (EDAX) analyses. XRD analysis indicates the preferential orientation of catalytically active {111} planes in Pd nanoparticles. A plausible mechanism has been proposed for the formation of anisotropic Pd nanoparticles
ΠΠ¦ΠΠΠΠ ΠΠΠΠ¦ΠΠΠ’Π ΠΠ¦ΠΠ Π ΠΠ‘Π’ΠΠΠ ΠΠΠΠΠ Π ΠΠ¦ΠΠΠ’ΠΠ Π CD14 Π ΠΠΠΠΠΠ Π£ ΠΠΠ§-ΠΠΠ€ΠΠ¦ΠΠ ΠΠΠΠΠΠ«Π₯ ΠΠΠ’Π ΠΠΠΠ’ΠΠΠΠ ΠΠΠΠΠ’ΠΠ
Chronic immune activation is one of the main causes of HIV disease progression. Bacterial components passed to the bloodstream from the gut as a result of microbial translocation, are known to induce immune activation. Component of Gram-negative bacteriaβs cell walls, the lipopolysaccharide (LPS), is considered to be the major marker of microbial translocation. Through the activation of myeloid cells (predominantly monocytes) LPS causes the secretion of soluble CD14, thus making it a marker of LPS bioactivity. Besides sCD14 was shown to correlate with immune status in HIVinfected patients and to be an independent predictor of disease progression.Hypothesis: opiates increase microbial translocation from the gut in HIV-infected patients that is manifested by a higher concentration of sCD14 in plasma.Aim: to estimate the influence of opiate use on the level of sCD14 in plasma of HIV-infected patients.Materials and methods. Longitudinal study of 351 HIV positive individuals. Concentration of sCD14, was evaluated at 3 time points: baseline, after 12 and 24 months. Following groups were studied: 1) current opiate users β opiate use within past 30 days; 2) opiate users, who denied consumption of opiates within past 30 days; 3) people claiming to never have used opiates.Results. In dynamic assessment sCD14 mean was significantly higher in current opiate users (2222,46Β±39,02 ng/ml) against patients who denied opiates within past 30 days (1930Β±597 ng/ml) and those, claiming to never have used opiates (1915Β±577 ng/ml) (p<0,001).Conclusion. Opiate use in the course of HIV disease leads to increase in LPS induced monocyte activation which therefore signifies more intensive microbial translocation.Π₯ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΡ ΠΈΠΌΠΌΡΠ½Π½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΎΠ΄Π½ΠΈΠΌ ΠΈΠ· ΠΎΡΠ½ΠΎΠ²Π½ΡΡ
ΡΠ°ΠΊΡΠΎΡΠΎΠ² ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π° ΠΠΠ§-ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ. ΠΠ½Π°ΡΠΈΡΠ΅Π»ΡΠ½Π°Ρ ΡΠΎΠ»Ρ Π² Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΈΠΌΠΌΡΠ½Π½ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ ΠΏΡΠΈΠ½Π°Π΄Π»Π΅ΠΆΠΈΡ ΡΡΠ°Π½ΡΠ»ΠΎΠΊΠ°ΡΠΈΠΈ Π±Π°ΠΊΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΡΡ
ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠΎΠ² ΠΈΠ· ΠΊΠΈΡΠ΅ΡΠ½ΠΈΠΊΠ° Π² ΠΊΡΠΎΠ²ΠΎΡΠΎΠΊ, Π² ΠΏΠ΅ΡΠ²ΡΡ ΠΎΡΠ΅ΡΠ΅Π΄Ρ Π»ΠΈΠΏΠΎΠΏΠΎΠ»ΠΈΡΠ°Ρ
Π°ΡΠΈΠ΄Π° (ΠΠΠ‘) ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΉ ΡΡΠ΅Π½ΠΊΠΈ Π³ΡΠ°ΠΌΠΎΡΡΠΈΡΠ°ΡΠ΅Π»ΡΠ½ΡΡ
ΠΌΠΈΠΊΡΠΎΠΎΡΠ³Π°Π½ΠΈΠ·ΠΌΠΎΠ². Π Π°ΡΡΠ²ΠΎΡΠΈΠΌΠ°Ρ ΡΠΎΡΠΌΠ° ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠ° CD14 (sCD14) ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠΌ ΠΌΠΎΠ½ΠΎΡΠΈΡΠ°ΡΠ½ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ, ΠΈΠ½Π΄ΡΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΠΠ‘. ΠΠΈΠΏΠΎΡΠ΅Π·Π° ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ: Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΠΠ§-ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠ΅ΠΉ ΠΏΠΎΡΡΠ΅Π±Π»Π΅Π½ΠΈΠ΅ ΠΎΠΏΠΈΠ°ΡΠΎΠ² ΡΠΏΠΎΡΠΎΠ±ΡΡΠ²ΡΠ΅Ρ ΡΡΠΈΠ»Π΅Π½ΠΈΡ ΠΌΠΈΠΊΡΠΎΠ±Π½ΠΎΠΉ ΡΡΠ°Π½ΡΠ»ΠΎΠΊΠ°ΡΠΈΠΈ ΠΈΠ· ΠΊΠΈΡΠ΅ΡΠ½ΠΈΠΊΠ°, ΠΏΡΠΎΡΠ²Π»ΡΡΡΠ΅ΠΉΡΡ Π±ΠΎΠ»Π΅Π΅ Π²ΡΡΠΎΠΊΠΎΠΉ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠ΅ΠΉ sCD14 Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ: ΠΎΡΠ΅Π½ΠΈΡΡ Π²Π»ΠΈΡΠ½ΠΈΠ΅ ΡΠΏΠΎΡΡΠ΅Π±Π»Π΅Π½ΠΈΡ ΠΎΠΏΠΈΠ°ΡΠΎΠ² Π½Π° ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡ sCD14 Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΠΠ§-ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠ΅ΠΉ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ: Ρ 351 Π±ΠΎΠ»ΡΠ½ΠΎΠ³ΠΎ ΠΠΠ§-ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠ΅ΠΉ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Π° ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡ ΡΠ°ΡΡΠ²ΠΎΡΠΈΠΌΠΎΠ³ΠΎ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠ° CD14 Π² ΠΏΠ»Π°Π·ΠΌΠ΅ Π² ΡΡΡΡ
Π²ΡΠ΅ΠΌΠ΅Π½Π½ΡΡ
ΡΠΎΡΠΊΠ°Ρ
: ΠΏΡΠΈ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΈΠΈ Π² ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅, ΡΠ΅ΡΠ΅Π· 12 ΠΈ 24 ΠΌΠ΅Ρ. Π‘ΠΎΠΏΠΎΡΡΠ°Π²Π»Π΅Π½Ρ Π·Π½Π°ΡΠ΅Π½ΠΈΡ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ sCD14 Π² Π³ΡΡΠΏΠΏΠ°Ρ
: 1) Π°ΠΊΡΠΈΠ²Π½ΡΡ
ΠΏΠΎΡΡΠ΅Π±ΠΈΡΠ΅Π»Π΅ΠΉ ΠΎΠΏΠΈΠ°ΡΠΎΠ²; 2) Π½Π°ΡΠΊΠΎΠΏΠΎΡΡΠ΅Π±ΠΈΡΠ΅Π»Π΅ΠΉ, ΠΎΡΡΠΈΡΠ°ΡΡΠΈΡ
ΡΠΏΠΎΡΡΠ΅Π±Π»Π΅Π½ΠΈΠ΅ ΠΎΠΏΠΈΠ°ΡΠΎΠ² Π·Π° ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΠ΅ 30 Π΄Π½Π΅ΠΉ; 3) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΎΡΡΠΈΡΠ°ΡΡΠΈΡ
ΡΠ°ΠΊΡ ΡΠΏΠΎΡΡΠ΅Π±Π»Π΅Π½ΠΈΡ ΠΎΠΏΠΈΠ°ΡΠΎΠ² Π² Π°Π½Π°ΠΌΠ½Π΅Π·Π΅.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ: Ρ Π°ΠΊΡΠΈΠ²Π½ΡΡ
ΠΎΠΏΠΈΠ°ΡΠ½ΡΡ
Π½Π°ΡΠΊΠΎΠΏΠΎΡΡΠ΅Π±ΠΈΡΠ΅Π»Π΅ΠΉ Π²ΡΡΠ²Π»Π΅Π½ΠΎ Π·Π½Π°ΡΠΈΠΌΠΎ Π±ΠΎΠ»Π΅Π΅ Π²ΡΡΠΎΠΊΠΎΠ΅ ΡΡΠ΅Π΄Π½Π΅Π΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ sCD14 Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ (2213Β±596 Π½Π³/ΠΌΠ») Π² ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΈ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌΠΈ, Π½Π΅ ΡΠΏΠΎΡΡΠ΅Π±Π»ΡΠ²ΡΠΈΠΌΠΈ ΠΎΠΏΠΈΠ°ΡΡ Π·Π° ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΠ΅ 30 Π΄Π½Π΅ΠΉ (1930Β±597 Π½Π³/ΠΌΠ»), ΠΈ Π»ΠΈΡΠ°ΠΌΠΈ, ΠΎΡΡΠΈΡΠ°ΡΡΠΈΠΌΠΈ ΡΠΏΠΎΡΡΠ΅Π±Π»Π΅Π½ΠΈΠ΅ ΠΎΠΏΠΈΠ°ΡΠΎΠ² (1915Β±577 Π½Π³/ΠΌΠ») (Ρ<0,001).ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅: ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΠΊΠ°Π·ΡΠ²Π°ΡΡ, ΡΡΠΎ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΠΠ§-ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠ΅ΠΉ ΡΠΏΠΎΡΡΠ΅Π±Π»Π΅Π½ΠΈΠ΅ ΠΎΠΏΠΈΠ°ΡΠΎΠ² ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΡ ΠΊ ΡΡΠΈΠ»Π΅Π½ΠΈΡ ΠΠΠ‘-ΠΈΠ½Π΄ΡΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΌΠΎΠ½ΠΎΡΠΈΡΠ°ΡΠ½ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ, ΡΡΠΎ, Π² ΡΠ²ΠΎΡ ΠΎΡΠ΅ΡΠ΅Π΄Ρ, ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΠ΅Ρ ΠΎ Π±ΠΎΠ»Π΅Π΅ ΠΈΠ½ΡΠ΅Π½ΡΠΈΠ²Π½ΠΎΠΉ ΡΡΠ°Π½ΡΠ»ΠΎΠΊΠ°ΡΠΈΠΈ Π±Π°ΠΊΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΡΡ
ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠΎΠ²
- β¦